Pear Therapeutics Profit Margin

The latest profit margin for PEAR is 195.19% as of December 2022. That compares with -2220.12% in the prior-year period — up 108.8% year over year. That is above the sector sector average of 21.34%. Investors often review this figure alongside Pear Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PEAR's profit margin moved from -2220.12% to 195.19% — a 108.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pear Therapeutics's valuation or profitability profile.

Against its sector companies, PEAR currently prints 195.19% for profit margin, while the sector average sits near 21.34%. That is roughly 814.6% above the sector mean. Large gaps often invite a closer look at Pear Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Pear Therapeutics converts resources into returns. At 195.19%, PEAR may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2220.12% in the prior-year period — up 108.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PEAR's profit margin (195.19%), review year-over-year change from -2220.12%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.